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Prognostic significance of metallothionein in B-cell lymphomas
Christian Bjørn Poulsen, Rehannah Borup, Niels Borregaard, Finn Cilius Nielsen, Michael Boe Møller, and Elisabeth Ralfkiaer
We have investigated metallothionein (MT)
I and II mRNA and protein in B-cell lympho-
mas with particular reference to diffuse
large B-cell lymphoma (DLBCL). The mRNA
profiling was performed on Affymetrix ar-
rays and showed up-regulated MT mRNA in
15 of 48 DLBCLs, including 12 of 23 acti-
vated B-cell (ABC) and 3 of 9 type-3
lesions. In contrast, MT mRNA was low to
undetectable in 16 germinal center B-cell
(GCB)–type DLBCLs. Only 1 of 15 pa-
tients with up-regulated MT mRNA
achieved a sustained remission, suggest-
ing that up-regulated MT mRNA consti-
tutes a significant risk factor for treat-
ment failure. This was confirmed in 2
independent series, which showed signifi-
cantly shorter 5-year survival in DLBCL
with high versus low MT-IIa levels. By
immunohistology, MT was shown to be
present in both macrophages and lym-
phoma cells. The proportion of MT-posi-
tive macrophages did not correlate with
the survival. In contrast, in 115 DLBCLs,
MT labeling of more than 20% lymphoma
cells was associated with a significantly
poorer 5-year survival, independent of
the age, stage, or International Prognos-
tic Index. Taken together, it is suggested
that both increased MT mRNA and MT
protein expression by more than 20%
lymphoma cells constitute independent
risk factors in DLBCL. (Blood. 2006;108:
3514-3519)
© 2006 by The American Society of Hematology
Introduction
The metallothioneins (MTs) are low-molecular-weight (6-7 kDa)
nonenzymatic proteins consisting of 60 to 68 amino acids. Four
subtypes are recognized (MT-I to MT-IV). Among these, MT-I and
MT-II are the major forms. They are encoded by genes located on
the same chromosome (no. 16 in humans), they are regulated and
expressed coordinately, and their distribution and biologic func-
tions are analogous.1,2 Both proteins contain 2 globular, cystein-
rich domains, which can bind essential and toxic metals, such as
zinc, copper, cadmium, and mercury. A main function is to act as an
intracellular zinc reservoir.3 Furthermore, there are indications that
the MTs are also involved in the protection against DNA damage,
oxidative stress, and apoptosis.1,4-6
Several observations have indicated that altered MT expression
is important for diseases in humans, including cancer, which often
up-regulates MT compared with normal cells.5,7,8 Moreover, in-
creased MT levels have been associated with high-grade histology
and an aggressive behavior in several of types of cancer.5,9-11
So far, most studies of MT in malignant diseases have been
performed in epithelial tumors. Very limited information is
available about the expression of MT in lymphomas. In this
study, we have investigated 141 B-cell lymphomas for MT
protein expression by immunohistology. Furthermore, MT mRNA
levels were investigated by expression profiling in 48 diffuse
large B-cell lymphomas (DLBCLs) previously classified into 3
groups (germinal center B-cell [GCB], activated B-cell [ABC],
and type-3) on Affymetrix arrays. The results indicate that
increased MT mRNA and protein may constitute an independent
risk factor in DLBCL.
Materials and methods
Biopsies
Formalin-fixed, paraffin-embedded specimens of 131 B-cell lymphomas
sampled during the period 1982 to 2004 were collected from the archives at
the Department of Pathology, Rigshospitalet, University of Copenhagen.
An additional 10 cases were kindly made available from the Department of
Pathology, Odense University Hospital. Only specimens obtained at
diagnosis, prior to treatment, were included. All cases were reviewed by
histology and immunohistology using standard panels of antibodies (ie,
CD20, CD79a, CD10, CD21, CD23, CD3, CD5, Bcl-2, and cyclin D1). The
samples were then classified in accordance with the World Health Organiza-
tion (WHO)26 and comprised 115 DLBCLs, 11 follicular lymphomas (FLs),
2 mantle cell lymphomas (MCLs), 7 small lymphocytic lymphomas
(SLLs), and 6 cases of multiple myeloma (MM). Of the DLBCLs, 86 were
primary nodal and 29 were primary extranodal at presentation with
involvement of the tonsil (9 cases), salivary glands (4 cases), thyroid
(3 cases), testis (3 cases), bone (2 cases), nasal cavity (1 case), cervix uteri
(1 case), liver (1 case), breast (1 case), kidney (1 case), pericardium (1
case), rhinopharynx (1 case), and skin (1 case).
Clinical data and survival
The clinical records were reviewed in all of the DLBCL patients with
particular reference to age, site of initial involvement, stage at diagnosis,
response to treatment, and survival. Information on the International
Prognostic Index (IPI) could be retrieved in 74 of the cases. All patients
were treated using anthracyclin-based regimens (CHOP [cyclophospha-
mide, vincristine, prednisone] or CHOP-like), supplemented in 6 patients
with additional antibody therapy (eg, rituximab). Survival was calculated
from the day of diagnosis until death or the date of last follow-up. Overall
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survival duration curves were plotted according to the Kaplan and Meier
method.12 The log-rank test was used to assess the differences between the
survival curves, and nominal P values were calculated.
Group comparisons were done using 2-sided, paired Student t test
(equal variance assumed).
Immunohistology
Sections of formalin-fixed, paraffin-embedded biopsies were heated in a
Milestone Micromed microwave oven (Sorisole, Italy) in citrate buffer (pH
6) for 15 minutes, incubated 60 minutes at room temperature with a 1:40
dilution of DAKO-MT (clone, E9; DAKO, Carpinteria, CA) reactive with
MT-I and MT-II in routinely processed histologic samples,13 and stained in
the Techmate 500 Immunostainer (DAKO, Glostrup, Denmark), using the
DAKO Envision K5007 as a secondary antibody. Since the results
suggested that some of the MT-positive cells represented macrophages,
samples were also stained using CD68 (PGM1) on adjacent sections.
As a preliminary approach to scoring, all specimens were screened by 2
authors (C.B.P., E.R.) to obtain an overall impression of the reactivity
patterns. Furthermore, in 20 randomly selected DLBCLs, the number of
MT-positive tumor cells was counted in 10 representative areas at 400 
magnification. These results showed that 4 broad categories could be
distinguished: no/occasional ( 5%); few (5%-20%); moderate (20%-
50%); and many ( 50%) MT-positive lymphoma cells. In general, the
intensity of the staining paralleled the number with weak to moderate
staining reactions in cases with few MT-positive tumor cells and stronger
reactions in cases with more MT-positive tumor cells. Similarly, for
macrophages, 3 categories could be distinguished: few (), moderate
(), and many () MT-positive tumor-infiltrating macrophages.
Therefore, for the scoring of the entire series, this semiquantitative scoring
system was adopted. All samples were scored independently by 2 authors
(C.B.P., E.R.) and were in case of disagreement reviewed in consensus.
Controls were included in all experiments and consisted of autopsy
specimens of normal liver and kidney. In these controls, strong staining was
seen of both nuclei and cytoplasm in proximal tubuli and hepatocytes.
mRNA expression profiling
Frozen tissue kept at80°C was available from 48 of the DLBCLs and was
subjected to expression profiling as described.14 Briefly, from each case,
5 g purified RNA was used to generate biotin-labeled antisense cRNA.
After fragmentation at 94°C for 35 minutes, the labeled cRNA samples
were hybridized for 16 hours to Affymetrix HG-U133A arrays (Affymetrix,
Santa Clara, CA), washed, and stained with phycoerythrin-conjugated
streptavidin (SAPE) and scanned in the Affymetrix GeneArray 2500
scanner to generate fluorescent images. All procedures were as described in
the Affymetrix GeneChip protocol. The image files (cel files) were imported
into the software package DNA-Chip Analyzer (C. Li and W. H. Wong
[www.dchip.org]). The array files were normalized and expression values
calculated as described.14 Samples were categorized as being GCB, ABC,
and type-3 by hierarchic clustering using a list of 78 classifier genes, as
already published.15
For validation, data from 2 independent studies of 240 newly diagnosed
DLBCLs analyzed on the Lymphochip platform16 and 176 newly diagnosed
DLBCLs with available Affymetrix HU133 A  B data sets17 were
downloaded from the Internet (Rosenwald et al16; http://llmpp.nih.gov/
DLBCL/ and Monti et al17; http://www.broad.mit.edu/cgi-bin/cancer/
publications/pub_paper.cgi?modeview&paper_id102) together with the
relevant clinical information. Using this approach, data on MT-IIa mRNA
levels and survival could be retrieved and analyzed from 238 patients in the
Rosenwald et al study16 and from 130 patients in the study by Monti et al.17
Ethics
This study was approved by the local ethics committee (journal no.
01-226/02) and the Danish Data Protection Agency (journal no. 2002
111129A). Informed consent was obtained from participants in accordance
with the Declaration of Helsinki.
Results
MT mRNA expression in DLBCL
mRNA extracted from frozen tissues from 48 of the DLBCLs was
examined by global expression profiling on Affymetrix arrays.
Similar to other reports,18-20 the tumors could be grouped into 3
categories depending upon the differential expression of 78 genes
as described in our previously developed classifier model: GCB
(n  16), ABC (n 23), and type-3 (n 9).15 A further analysis of
other genes differentially expressed in these groups showed that the
genes encoding mRNA MT-IIa and the different isoforms of MT-I
(eg, MT-IL, G, H, X, G, F, E, K) were up-regulated (above mean) in
12 of 23 of the ABC tumors and in 3 of 9 type-3 tumors, but were
low to undetectable in the 16 GCB lesions (Figure 1A-B). A
correlation with the treatment outcome showed that only 1 of 15
patients with up-regulated MT mRNA achieved a sustained com-
plete remission (CR). The remaining either showed only a tempo-
rary response (n 4) or had refractory disease (n 10). Con-
versely, in the 33 patients with low MT mRNA levels, 17 achieved
a sustained CR, 9 achieved a temporary CR but relapsed, and 7 had
refractory disease. These data suggested that up-regulated MT
mRNA may identify a particular subgroup of ABC and type-3
DLBCL with a poor response to conventional chemotherapy and a
potentially aggressive behavior.
To address this possibility in more detail, the survival of patients
with high versus low MT mRNA was investigated both in this
series and in another 2 independent data sets (Rosenwald et al16 and
Monti et al17). In our series of 48 patients, a tendency toward an
inferior survival was seen in patients with high MT mRNA
compared with those with low MT mRNA (Figure 2A). However,
this difference did not reach statistical significance, presumably
due to the relatively small number of patients. In contrast, among
238 patients downloaded from the publication of Rosenwald et al,16
those with high (above mean) MT-IIa mRNA showed a signifi-
cantly poorer survival than those with lower MT-IIa levels
Figure 1. MT-I and MT-II expression in GCB, ACB, and type-3 subtypes of
DLBCL. (A) MT-I and MT-II mRNA expression in 48 DLBCLs previously classified as
GCB (n  16), ABC (n  23), and type-3 (n  9) by expression profiling on Affymetrix
arrays.15 For MT-I, the expression of 7 different isoforms represented on the
Affymetrix 133A GeneChip is illustrated. C indicates complete remission; r, recurrent
disease; and R, refractory disease. (B) MT-II mRNA expression values (arbitrary
units) in the 3 different subtypes of DLBCL (GCB, ABC, type-3). CI indicates
confidence interval.
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(Figure 2B). A similar difference (P  .05) was observed when
data from 130 patients from the study by Monti et al17 were
analyzed (data not shown).
MT protein expression
To characterize MT expression at the protein level, an extended
series of pretreatment, diagnostic biopsies from 141 B-cell lympho-
mas sampled during the period 1982 to 2004 were examined by
immunohistology using anti-MT antibody (E9) reactive with MT-I
and MT-II in formalin-fixed specimens.13 This series included the
48 DLBCLs analyzed on Affymetrix arrays as well as samples from
an additional 67 DLBCLs. Furthermore, specimens from 20 small
B-cell lymphomas (“Materials and methods”) and 6 multiple
myelomas were investigated.
In all the B-cell lymphomas, the antibody stained a population
of CD68 dendritic cells, representing tumor-infiltrating macro-
phages (Figure 3). MT labeling of the macrophages was prominent
in the cytoplasm, but the nuclei were also weakly stained in most
cases. The number of MT-positive tumor-infiltrating macrophages
was most abundant in DLBCLs (Table 1), but had no impact on the
5-year survival (Figure 4).
MT expression by the lymphoma cells was more restricted. As
shown in Table 2, significant numbers of MT-positive tumor cells
( 20%) were observed in 21 of 115 of the DLBCLs. In the
remaining B-cell lymphomas, no or only occasional MT-positive
tumor cells were identified. Labeling of the lymphoma cells was
mainly nuclear, although cytoplasmic reactivity was also present in
some cases (Figure 5). No significant differences with respect to
age, stage, or IPI at diagnosis were observed between DLBCLs
with MT-positive tumor cells above or below 20% (Table 3).
However, the survival at 5 years was significantly poorer in the
former category (Figure 6), suggesting that more than 20%
MT-positive lymphoma cells constitutes an independent risk factor
in DLBCL. Small, reactive, tumor-infiltrating lymphocytes were
MT negative (Figure 5).
Correlation between the number of MT-positive tumor cells and
macrophages in individual DLBCLs is summarized in Table 4. As
shown, no specific correlation was identified. For example, among
18 DLBCLs with more than 50% MT-positive tumor cells, 6
contained few MT-positive macrophages, 6 contained an intermedi-
ate number, and 6 contained many MT-positive macrophages.
Similarly, among 25 cases with many MT-positive macrophages,
only 7 contained more than 20% positive lymphoma cells. Hence, it
is less likely that phagocytosis of MT produced in lymphoma cells
contributed significantly to the observed MT staining of
macrophages.
MT mRNA versus protein expression
MT-II and the several different isoforms of MT-I are coordinately
expressed under a number of conditions.1,21 This was also seen in
our study, as illustrated in Figure 1A. For comparison between the
MT mRNA and protein expression levels, we focused on MT-II.
The results for 48 DLBCLs in which samples were available for
both immunohistology and expression profiling on Affymetrix
arrays are illustrated in Figure 7A-B and showed significantly
increased MT mRNA (mean, 4253) in lymphomas with abundant
() numbers of MT-positive macrophages compared with
those with few () or moderate () numbers (mean, 1598;
P  .001). A similar correlation was seen between the MT mRNA
expression level and the number of MT-positive tumor cells
detected by immunohistology—that is, mean of 2737 in DLBCLs
Figure 2. MT and survival in DLBCLs. Survival in DLBCL with high versus low MT
mRNA in this series (A) and the series from the Rosenwald et al study17 (B).
Figure 3. MT-I and MT-II staining of tumor-infiltrating macrophages. Adjacent
sections of a DLBCL stained for MT-I and MT-II (A, DAKO-MT  600) and CD68 (B,
PGM1  600) showing numerous MT-positive stromal cells with a dendritic morphol-
ogy (A), similar to the pattern with CD68 (B). In panels C and D, DLBCL with few (C)
and abundant (D) numbers of MT-positive tumor-infiltrating macrophages is shown
(DAKO-MT  400). In these cases, only very occasional tumor cells (asterisks in C)
are stained with a weak nuclear reactivity.
Table 1. MT expression by macrophages in different types
of B-cell lymphomas
Diagnoses
No. patients
   Total
DLBCL 52 37 26 115
FL, grades I II 8 0 0 8
FL, grade III 3 0 0 3
MCL 2 0 0 2
MM 5 1 0 6
SLL 7 0 0 7
 indicates few; , moderate; , abundant numbers of MT-positive
macrophages; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL,
mantle cell lymphoma; MM, multiple myeloma; and SLL, small lymphocytic lym-
phoma.
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with more than 20% positive tumor cells versus mean of 1814 in
DLBCLs with less than 20% positive tumor cells (P  .04). These
data indicated that the MT mRNA level determined by expression
profiling in crude extracts of DLBCLs correlated with, and was
contributed to, by MT produced in both lymphoma cells and
macrophages.
Discussion
The MTs are single-chain 6- to 7-kDa proteins with a high content
of cystein, sulfur, and metal. Four subtypes are recognized in
humans, MT-I and MT-II, which are widespread, and MT-III and
MT-IV, which are more restricted in distribution. All the MTs
contain 2 metal-binding domains, a C-terminal  and a N-terminal
	 domain. Both are rich in cysteins, which can bind essential and
toxic metals. The MT genes are located on chromosome 16 in
humans and can be activated by a variety of stimuli, including
metal ions, oxidative stress, cytokines, glucocorticoids, growth
factors, and hypoxia.2,8,22,23 The MTs have established roles in
metal homeostasis and in the protection against reactive oxygen
species. Furthermore, there are indications that the MTs are
involved in cell proliferation, in the protections against DNA
damage, in the prevention of apoptosis, and in the acquisition of
resistance to a variety of commonly used cancer chemothera-
pies.8,21-24 Accordingly, it is conceivable that altered MT expression
may play a role for neoplastic disorders.
Expression of the MTs has been studied in considerable detail in
human carcinomas, and these studies have shown that the MTs are
often up-regulated in malignant compared with normal cells.
Furthermore, it has been shown that up-regulated MT associates
with high-grade histology and an aggressive behavior in many
types of carcinoma.5 In contrast, very limited information is
available about MT expression in lymphoma. Thus, to date, only 2
previous reports of a total of 12 lymphomas of different subtypes
are available.7,25
In an attempt to investigate whether MTs have implications in
lymphoma, we have examined MT mRNA and protein expression
in mature B-cell lymphomas with particular reference to DLBCL,
which constitutes the most frequent subtype of B-cell lymphoma in
Western countries. Although classified as one disease by the REAL
and WHO classifications,26 several more recent investigations have
indicated that DLBCL is likely to encompass more than one
biologic entity. Thus, it has been shown that different clinical
subtypes can be recognized by phenotypic and genotypic investiga-
tions at the protein, mRNA, and DNA level.27-29 For example, it has
Table 3. Clinical data in DLBCLs with low versus high MT-I and MT-II
expression in the tumor cells
Low expression,
less than 20%
High expression,
more than 20%
Age, y (no. patients) 64.2 (97) 65.4 (18)
Stage (no. patients) 2.58 (73) 2.65 (17)
IPI (no. patients) 2.31 (59) 2.40 (15)
5-year overall survival, % (no. patients) 40.7 (97) 12.0 (18)
Figure 4. Survival in 115 DLBCLs in relation to the proportion of MT-positive
tumor-infiltrating macrophages. No significant differences were seen between the
3 groups of few, moderate, and many (A), between few versus moderate/many (B), or
between few/moderate versus many (C) MT-positive macrophages.
Table 2. MT expression in tumor cells from different types
of B-cell lymphomas
Diagnosis
MT-positive tumor cells, no. patients
Less than
5%
5% to
20%
20% to
50%
More than
50% Total
DLBCL 72 22 3 18 115
FL, grades I II 7 1 0 0 8
FL, grade III 3 0 0 0 3
MCL 2 0 0 0 2
MM 6 0 0 0 6
SLL 7 0 0 0 7
DLBCL indicates diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL,
mantle cell lymphoma; MM, multiple myeloma; and SLL, small lymphocytic lym-
phoma.
Figure 5. A DLBCL with strong MT staining of a majority of the tumor cells in
both nuclei and cytoplasm (A, DAKO-MT  200; B, DAKO-MT  600). Note that
small reactive lymphocytes (arrow) are MT negative.
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been shown in this and other laboratories that, at the least, 3
subgroups with different outcomes can be distinguished depending
upon the mRNA expression profiles. These include DLBCL with a
GCB-like mRNA signature, DLBCL with an ABC-like signature,
and an intermediate, so-called type-3 category. Whereas the
GCB-like DLBCL generally shows an indolent course, the behav-
ior of the ABC and type-3 lesions is more aggressive.15,18,19,30-32
Here, we show that mRNA encoding MT-I and MT-II is
differentially up-regulated in half of DLBCLs with an ABC
signature and in one third of type-3 tumors, but is low to
undetectable in DLBCLs with a GCB signature. Furthermore, it is
shown that up-regulated MT-I and MT-II mRNA in DLBCL
correlates with treatment failure and a short survival. This was
evident both in this series and in another 2 independent data sets
published by Rosenwald et al (2002)16 and Monti et al (2005).17
Since the genes encoding MT-I and MT-II are not contained in
either our or other previously reported classifier lists for distinction
between ABC and GCB DLBCLs,15 they are clearly not merely
markers of ABC versus GCB tumors, but rather represent addi-
tional markers for a particular subgroup of DLBCLs with a poor
response to conventional chemotherapy and a short survival. This
was supported by the results obtained by immunohistology, which
showed that MT protein expression by the lymphoma cells in an
extended series of 115 DLBCLs, 20 small B-cell lymphomas, and 6
multiple myelomas was confined to the DLBCLs. Furthermore, in
the DLBCLs the presence of more than 20% MT-positive lym-
phoma cells was a significant risk factor associated with a short
survival, independent of the age, stage, and IPI.
Very few previous reports have specifically addressed the MT
mRNA and protein levels in lymphomas, and it is presently not
clear how the MTs influence the behavior of DLBCLs at the
molecular level. One obvious possibility is that enhanced MTs can
confer resistance to conventional chemotherapies commonly used
in treating DLBCL (eg, anthracyclins and cyclophosphamide).21,24
Indeed, studies have shown that MTs can inhibit anthracyclin-
induced mitochondrial cytochrome c release and caspase-3 activa-
tion,33,34 and can mediate intracellular sequestration of cyclophos-
phamide.35,36 Thus, it is possible that up-regulated MT mRNA and
protein may identify a particular subgroup of DLBCL, which could
benefit from more intensive therapy and/or from other treatment
modalities than conventional CHOP or CHOP-like regimens.
Potentially interesting options in this respect are electron-affinic
compounds such as motexafin gadolinium, which increases oxida-
tive stress, enhances expression of metal response element–binding
transcription factor-1–regulated genes, including MT, and can
induce cell-cycle arrest and apoptosis in B-cell lines in vitro under
appropriate conditions.37 Since cells may be more susceptible if
already subjected to oxidative stress, both the MThigh DLBCL
described in this report and the recently identified so-called
OxPhos consensus cluster of DLBCL, characterized by increased
levels of several genes associated with oxidative phosphoryla-
tion,17 could constitute interesting targets for future investigations
in clinical trials.
In a previous study, it was suggested that MT may constitute a
“malignancy marker” in B-cell lymphomas based on the observa-
tion that tumor-infiltrating lymphocytes in 11 gastrointestinal tract
lymphomas were MT negative, unlike the lymphoma cells that
were positive to varying extents.25 The results from this investiga-
tion support the view that tumor-infiltrating lymphocytes in B-cell
lymphomas are generally MT negative. However, it is also shown
that MT protein in these conditions is not confined to the lymphoma
cells, but that a proportion of tumor-infiltrating macrophages is
often MT positive, especially in DLBCL. Since no specific
correlation was identified between the number of MT-positive
macrophages and lymphoma cells in this series, the observed MT
staining of macrophages presumably did not result from phagocyto-
sis, but rather reflected endogenous synthesis. In keeping with this
assumption are the observations that MTs can be induced in
monocytes under in vitro conditions and that MT-positive macro-
phages are also recruited to mice brain tissue subjected to
cryoinjury.38,39
The functional implications of the MT-positive tumor-infiltrat-
ing macrophages seen in this study and the stimuli that induce them
Figure 6. Survival in 115 DLBCLs in relation to the proportion of MT-positive
lymphoma cells. No difference was seen between tumors with no/occasional versus
few (5%-20%) MT-positive tumor cells (A). In contrast, a significantly poorer survival
was seen in patients with more than 20% MT-positive tumor cells compared with
those with less than 20% MT-positive tumor cells (B).
Figure 7. MT-II mRNA expression levels in 48 DLBCLs. MT-II mRNA expression
levels in 48 DLBCLs related to the number of MT-positive tumor cells (A) and
macrophages (B) determined by immunohistology. As shown, increased MT mRNA in
crude extracts correlated both with the number of MT-positive tumor cells and
macrophages.
Table 4. MT expression in tumor cells versus macrophages
in 115 DLBCLs
Macrophage
MT-positive tumor cells, no. patients
Less than
5%
5% to
20%
20% to
50%
More than
50%
 42 3 1 6
 17 13 1 6
 13 6 1 6
Total 72 22 3 18
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are not known. Of interest, in this report the proportion of
MT-positive macrophages in DLBCL did not seem to influence the
survival, although they correlated with and presumably contributed
to the MT mRNA levels measured in crude extracts. Hence, from a
clinical perspective, it is recommended that MT measurements of
crude extracts be supplemented with immunohistologic assess-
ments, which permit distinction between MT-positive lymphoma
cells and macrophages.
In conclusion, it is suggested that up-regulated MT-I and MT-II
mRNA and increased MT-I and MT-II protein expression by the
lymphoma cells constitute independent risk factors in DLBCL.
How the MTs influence the behavior of DLBCL at the molecular
level is unknown. However, it is tempting to assume that increased
proliferation, decreased apoptosis, and increased acquisition of
resistance to chemotherapy may be implicated. These issues will be
important to address in future investigations.
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